Regenxbio starts Phase 1/2 study for Duchenne gene therapy

 Company has initiated Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 

-  Company also enrolling newly active observational screening study, AFFINITY BEYOND, evaluating AAV8 antibody prevalence in boys with Duchenne 
-  Commercial-scale cGMP material from the REGENXBIO Manufacturing Innovation Center to be used in the clinical trial 
-  RGX-202 is a potential one-time AAV Therapeutic for the treatment of Duchenne and includes an optimized transgene for a novel microdystrophin and REGENXBIO's proprietary NAV® AAV8 vector

https://finance.yahoo.com/news/regenxbio-announces-phase-ii-trial-120500662.html